(3-((2,5-Dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid

Catalog No. :
ACBAXK632
CAS No. :
1449132-54-0
Molecular Formula :
C13H9BCl2FNO3
Molecular Weight :
327.93

IUPAC Name:(3-((2,5-dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid

(3-((2,5-Dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$429.00Login to see priceInquiryInquiry
1g97%$1075.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3-((2,5-Dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid
IUPAC Name(3-((2,5-dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid
MDL No.MFCD20040175
Molecular FormulaC13H9BCl2FNO3
Molecular Weight327.93
SMILESFC1=CC(C(NC2=CC(Cl)=CC=C2Cl)=O)=CC(B(O)O)=C1
InChI KeyRIYQHRIACCPXTP-UHFFFAOYSA-N
SynonymBoronic acid, B-[3-[[(2,5-dichlorophenyl)amino]carbonyl]-5-fluorophenyl]-;5-(2,5-Dichlorophenylcarbamoyl)-3-fluorobenzeneboronic acid, 97%(WS202139);(3-((2,5-dichlorophenyl)carbamoyl)-5-fluorophenyl)boronic acid
CAS No.1449132-54-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACBAXK632 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTLEX690 route compound structure diagram
    ACTLEX690871329-84-9 In Stock
  4. Then
  5. ACBAXK632 route product structure diagram
    ACBAXK6321449132-54-0
Inquiry

2. ACBAXK632 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBAXK632 route product structure diagram
    ACBAXK6321449132-54-0
Inquiry

Comments (0)